<DOC>
	<DOCNO>NCT00026897</DOCNO>
	<brief_summary>Patients undergo immunotherapy advance cancer IRB-approved protocol , receive immune cell adoptive transfer , less equal 50 % cell label In-111-oxine administer along remainder unlabeled cell . They undergo gamma-camera image next 0-7 day blood sample tumor site accessible minimal surgery ( low-risk biopsy ) may sample patient enumeration radiolabeled cell . End-points tumor normal organ image amount In-111 per gram tissue biopsy per ml . blood .</brief_summary>
	<brief_title>Trafficking Indium-III-Labeled Cultured Immune Cells Patients Undergoing Immunotherapy Advanced Cancer</brief_title>
	<detailed_description>Patients undergo immunotherapy advance cancer IRB-approved protocol , receive immune cell adoptive transfer , less equal 50 % cell label In-111-oxine administer along remainder unlabeled cell . They undergo gamma-camera image next 0-7 day blood sample tumor site accessible minimal surgery ( low-risk biopsy ) may sample patient enumeration radiolabeled cell . End-points tumor normal organ image amount In-111 per gram tissue biopsy per ml . blood .</detailed_description>
	<criteria>INCLUSION CRITERIA All patient 18 year age old . All patient enrol NCIapproved intramural immunotherapy protocol immune cell adoptively administer treat advanced cancer . EXCLUSION CRITERIA Patients receive less 3x10 ( 9 ) cell transfer exclude . Impaired patient unable give valid inform consent also exclude . Patients pregnant exclude . All exclusion criterion state parent immunotherapy protocol . Patients HIVinfected .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>Adoptive Immunotherapy</keyword>
	<keyword>Cellular Therapy</keyword>
	<keyword>Lymphocyte Migration</keyword>
	<keyword>Tumor Imaging</keyword>
</DOC>